Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
- PMID: 12112774
- DOI: 10.1002/ppul.10127
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
Abstract
We conducted a registry-based study to determine prognostic indicators of 8-year mortality and morbidity in young children with cystic fibrosis (CF). Patients ages 1-5 years from the 1990 U.S. Cystic Fibrosis Foundation (CFF) National Patient Registry served as the study cohort (N = 3,323). Registry data provided information on baseline characteristics in 1990, 8-year mortality, and clinical outcomes in 1998.P. aeruginosa respiratory infection was found to be a major predictor of morbidity and mortality. The 8-year risk of death was 2.6 times higher in patients who had respiratory cultures positive for P. aeruginosa in 1990 (95% confidence interval 1.6, 4.1) than in children without P. aeruginosa in their respiratory cultures. Culture-positive patients in 1990 also had a significantly lower percent predicted forced expiratory volume in 1 sec (FEV(1)) and weight percentile at follow-up, and they had an increased risk of continued P. aeruginosa respiratory infection and hospitalization for acute respiratory exacerbation in 1998. Among the other predictors of increased morbidity and mortality were lower baseline weight percentiles and number of CF-related hospitalizations during the baseline year.These findings confirm reports from previous smaller studies of outcomes among young children with CF, and highlight the potential to decrease the morbidity and mortality of young patients with CF through early intervention.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.J Infect Dis. 2001 Feb 1;183(3):444-52. doi: 10.1086/318075. Epub 2000 Dec 27. J Infect Dis. 2001. PMID: 11133376
-
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.J Pediatr. 2001 May;138(5):699-704. doi: 10.1067/mpd.2001.112897. J Pediatr. 2001. PMID: 11343046
-
Predictors of mortality in adults with cystic fibrosis.Pediatr Pulmonol. 2007 Jun;42(6):525-32. doi: 10.1002/ppul.20619. Pediatr Pulmonol. 2007. PMID: 17469153
-
Prevention of severe lower respiratory infections in patients with cystic fibrosis.Semin Respir Infect. 1989 Dec;4(4):266-71. Semin Respir Infect. 1989. PMID: 2516638 Review.
-
Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report.J Cyst Fibros. 2011 Jun;10 Suppl 2:S75-8. doi: 10.1016/S1569-1993(11)60011-8. J Cyst Fibros. 2011. PMID: 21658646
Cited by
-
The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.Pharm Res. 2017 Mar;34(3):507-528. doi: 10.1007/s11095-016-2050-x. Epub 2016 Oct 13. Pharm Res. 2017. PMID: 27738953 Review.
-
State of progress in treating cystic fibrosis respiratory disease.BMC Med. 2012 Aug 10;10:88. doi: 10.1186/1741-7015-10-88. BMC Med. 2012. PMID: 22883684 Free PMC article. Review.
-
Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis.J Clin Microbiol. 2015 Jul;53(7):2022-9. doi: 10.1128/JCM.00432-15. Epub 2015 Apr 15. J Clin Microbiol. 2015. PMID: 25878338 Free PMC article.
-
Environmental allergies and respiratory morbidities in cystic fibrosis.Pediatr Pulmonol. 2013 Sep;48(9):857-64. doi: 10.1002/ppul.22700. Epub 2012 Nov 9. Pediatr Pulmonol. 2013. PMID: 23143815 Free PMC article.
-
Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.Clin Infect Dis. 2015 Sep 1;61(5):707-15. doi: 10.1093/cid/civ377. Epub 2015 May 13. Clin Infect Dis. 2015. PMID: 25972024 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical